Results 1 to 10 of about 5,853 (155)

Pharmacokinetic Interaction Between Isavuconazole and Rifabutin in a Real-World Setting. [PDF]

Mycoses
ABSTRACT Background Since rifabutin has less severe drug interactions, it is preferred over rifampin when administered concomitantly with azole antifungals. However, limited data exist to evaluate this interaction. Methods This was a single‐centre study of hospitalised patients who received concomitant isavuconazole and rifabutin prior to plasma ...
Shah S, Clarke L, Lee T, Georgiades L, Smith BJ, Venkataramanan R, Rivosecchi RM.   +6 more
europepmc   +2 more sources

Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co-Infection Using a Rifampicin or Rifabutin-Based Regimen: A Retrospective Observational Case Series. [PDF]

Immun Inflamm Dis
ABSTRACT Introduction Co‐infection with tuberculosis (TB) is the leading cause of death in individuals infected with human immunodeficiency virus (HIV)‐1. Dolutegravir and lamivudine (DTG + 3TC) has recently been recommended as the preferred first‐line regimen for the treatment of new and treatment‐experienced HIV‐infected patients.
He J, He X, Xie X, Fu Y, Luo X, Peng Y, Xu B, Long H.   +7 more
europepmc   +2 more sources

Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety, and tolerability of BV100 (rifabutin for infusion) in healthy volunteers. [PDF]

Antimicrob Agents Chemother
Kemmer C, Hirsch M, Reh C, Davila M, Jung F, Husband L, Dale GE.   +6 more
europepmc   +1 more source

High-Throughput Screening of FDA-Approved Drugs for Antibacterial and Antibiofilm Activities Against Multidrug-resistant <i>Pseudomonas aeruginosa</i>. [PDF]

ACS Omega
Guo S, Li H, Liu B, Chen C, Liu H, Zhang Q.   +5 more
europepmc   +1 more source

Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis. [PDF]

J Infect Dis
Chen X, Ruiz-Gonzalez CE, Masias-Leon Y, Singh M, Nino-Meza OJ, Peloquin CA, Artemov D, Jain SK.   +7 more
europepmc   +1 more source

Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for <i>Helicobacter pylori</i> rescue treatment: a multicentre, open-label, non-inferiority randomised trial. [PDF]

Lancet Reg Health West Pac
Huang Y, Chen JN, Qiu SH, Guo YX, Li MX, Gao YN, Liang X, Han YH, Xu P, Wang J, Lu H.   +10 more
europepmc   +1 more source

Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacteriumabscessus. [PDF]

J Biol Chem
Nguyen TQ, Hamela C, Pang L, Liu Y, Giannini GC, Boeck L, Larrouy-Maumus G, Kremer L.   +7 more
europepmc   +1 more source

A macroevolution-inspired approach to reveal novel antibiotic resistance mechanisms. [PDF]

Elife
Subtil FT, Machado TFG, Douglas H, Kirkpatrick JM, Skehel M, Garza-Garcia A, de Carvalho LPS.   +6 more
europepmc   +1 more source

Rifabutin: A Repurposing Candidate for Mycobacterium abscessus Lung Disease

Frontiers in Microbiology, 2020
Thomas Dick, Thomas Dick
doaj   +1 more source

A Review on the Progress and Strategies of <i>Helicobacter pylori</i> Eradication Therapy for Patients With Penicillin Allergy. [PDF]

Gastroenterol Res Pract
Zhang Y, Suo B, Tian X, Li C, Ren X, Zhou K, Mi C, Wang Y, Ma L, Zhou L, Song Z.   +10 more
europepmc   +1 more source